Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 20/20 | 0.62 |
| ▸ | GAK | O14976 | 1/20 | 0.62 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.62 |
| ▸ | RIPK3 | Q9Y572 | 9/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14699037 | 0.88 | RIPK2 (0.69) | RIPK2GAKNOD2RIPK3 | |
| SCHEMBL2592937 | 0.85 | RIPK2 (0.69) | RIPK2GAKNOD2RIPK3 | |
| SCHEMBL14699060 | 0.84 | RIPK2 (0.58) | RIPK2GAKNOD2RIPK3 | |
| SCHEMBL14697941 | 0.81 | RIPK2 (0.59) | RIPK2GAKNOD2RIPK3 | |
| SCHEMBL14697939 | 0.80 | RIPK2 (0.71) | RIPK2RIPK3 | |
| SCHEMBL14697817 | 0.80 | RIPK2 (0.55) | RIPK2GAKNOD2RIPK3 | |
| SCHEMBL2595058 | 0.78 | RIPK2 (0.72) | RIPK2GAKNOD2RIPK3 | |
| SCHEMBL14697655 | 0.77 | RIPK2 (1.00) | RIPK2GAKNOD2RIPK3 | |
| SCHEMBL29508237 | 0.77 | RIPK2 (1.00) | RIPK2GAKNOD2RIPK3 | |
| SCHEMBL14697412 | 0.76 | RIPK2 (0.76) | RIPK2GAKNOD2RIPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10717711-B2 | Amino quinazolines as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-07-21 | — | — | US | disclosed |
| US-10717711-B2 | Amino quinazolines as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-07-21 | — | — | US | disclosed |
| US-20190194145-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-06-27 | — | — | US | disclosed |
| US-20190194145-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-06-27 | — | — | US | disclosed |
| US-20180258056-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-09-13 | — | — | US | disclosed |
| US-9994529-B2 | Amino quinazolines as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-12 | — | — | US | disclosed |
| US-9994529-B2 | Amino quinazolines as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-12 | — | — | US | disclosed |
| US-9994529-B2 | Amino quinazolines as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-12 | — | — | US | disclosed |
| US-20170152233-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-01 | — | — | US | disclosed |
| US-20170152233-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-01 | — | — | US | disclosed |
| US-20170152233-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-01 | — | — | US | disclosed |
| US-9604938-B2 | Amino quinazolines as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-03-28 | — | — | US | disclosed |
| US-9604938-B2 | Amino quinazolines as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-03-28 | — | — | US | disclosed |
| US-9604938-B2 | Amino quinazolines as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-03-28 | — | — | US | disclosed |
| EP-2744501-B1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-11-30 | — | — | EP | disclosed |
| EP-2744501-B1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-11-30 | — | — | EP | disclosed |
| US-20140206688-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-07-24 | — | — | US | disclosed |
| US-20140206688-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-07-24 | — | — | US | disclosed |
| EP-2744501-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2014-06-25 | — | — | EP | disclosed |
| WO-2013025958-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180258056-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | ABL1, MAP3K3, MAP4K2 | RIPK2 376/4885GAK 98/4885NOD2 4452/4885 |
| US-20190194145-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | ABL1, MAP3K3, MAP4K2 | RIPK2 376/4885GAK 98/4885NOD2 4452/4885 |
| US-20170152233-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | ABL1, MAP3K3, MAP4K2 | RIPK2 376/4885GAK 98/4885NOD2 4452/4885 |
| US-10717711-B2 | Amino quinazolines as kinase inhibitors | ABL1, MAP3K3, MAP4K2 | RIPK2 376/4885GAK 98/4885NOD2 4452/4885 |
| US-20140206688-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | ABL1, MAP3K3, MAP4K2 | RIPK2 373/4885GAK 120/4885NOD2 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.